Alveus Therapeutics
Redefining Weight Management
- Headquarters
- Philadelphia, Pennsylvania
- Employees
- 11–50
- Founded
- 2024
- Business Model
- B2B
- Website
- alveustx.com
- Total Funding
- $197.0M
- Last Round
- $37.0M Series AMar 2026
- Rounds
- 2
About
Alveus Therapeutics is a clinical-stage biopharmaceutical company developing next-generation therapies for obesity and metabolic diseases. Its lead asset ALV-100 is currently in Phase 1b clinical trials, targeting sustainable weight loss with superior tolerability and reduced treatment burden. The company was founded in early 2024 and raised a $197 million Series A to advance its differentiated therapeutic pipeline.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Create Free AccountFunding History
Investors
Sign up to view investors
Create a free account to see which investors have funded this company.
Create Free AccountSimilar Companies
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Biopharmaceutical services company
Specialty pharmaceutical company
Food technology company creating plant-based meat and dairy products that replicate the taste and...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.